{
  "emaEpar": [
    {
      "activeSubstance": "Midostaurin",
      "conditionIndication": "Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL).",
      "inn": "midostaurin",
      "marketingAuthorisationDate": "2017-09-18 00:00:00",
      "marketingAuthorisationHolder": "Novartis Europharm Ltd",
      "medicineName": "Rydapt",
      "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt"
    }
  ],
  "fdaDrugLabel": [
    {
      "brand": "RYDAPT",
      "indication": "1 INDICATIONS AND USAGE RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 ) 1.1 Acute Myeloid Leukemia RYDAPT is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test [see Dosage and Administration (2.1), Clinical Studies (14.1)]. Limitations of Use RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. 1.2 Systemic Mastocytosis RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).",
      "manufacturer": "Novartis Pharmaceuticals Corporation",
      "splSetId": "11fa3fc9-6776-49a6-b1c1-653f627c3e58"
    }
  ],
  "id": "Midostaurin",
  "nciThesaurus": {
    "casRegistry": "120685-11-2",
    "chebiId": "CHEBI:63452",
    "chemicalFormula": "C35H30N4O4",
    "definition": "A synthetic indolocarbazole multikinase inhibitor with potential antiangiogenic and antineoplastic activities. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.",
    "fdaUniiCode": "ID912S5VON",
    "identifier": "C1872",
    "preferredName": "Midostaurin",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1742",
      "C2089"
    ],
    "synonyms": [
      "CGP 41251",
      "CGP41251",
      "MIDOSTAURIN",
      "Midostaurin",
      "N-Benzoyl-Staurosporine",
      "N-Benzoylstaurosporine",
      "N-benzoyl-staurosporine",
      "PKC-412",
      "PKC412",
      "Rydapt",
      "midostaurin"
    ]
  }
}